203 Pb-VMT-α-NET Scintigraphy of a Patient With Neuroendocrine Tumor.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 36257061.
- Also identified by DOI 10.1097/RLU.0000000000004464 and PMC identifier 9762701.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In an end-stage midgut neuroendocrine tumor patient with carcinoid heart disease, right ventricular dysfunction, mildly reduced renal function, and refractory to 6 cycles of 177 Lu-HA-DOTATATE therapy, planar, and 22 hours SPECT/CT images were acquired after injection of 224 MBq of 203 Pb-VMT-α-NET to assess the feasibility of performing 212 Pb-VMT-α-NET therapy. A comparison of the 1.5 and 22 hours SPECT/CT images with 68 Ga-HA-DOTATATE PET/CT showed high uptake of 203 Pb-VMT-α-NET in liver metastases matching with the results of the PET/CT investigation.
Medical subject headings
- Neuroendocrine Tumors
- Organometallic Compounds